Australian researchers looking to source BPC-157 domestically no longer need to look overseas. BPC-157 is in stock at Australian Peptides and available for immediate dispatch across Australia this March 2026.

What Is BPC-157?

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protein sequence found in human gastric juice. First isolated and studied in the 1990s, it has since accumulated one of the more substantial research histories of any peptide in its class, with published literature spanning several decades and multiple research disciplines.

The compound is stable in gastric acid, which has made it a practical subject for a wide range of research methodologies. Its stability profile distinguishes it from many other peptides that degrade rapidly under similar conditions.

Areas of Research Interest

BPC-157 has been investigated across a notably broad range of research contexts:

• Tissue and wound research — among the earliest and most studied applications, with a large volume of published literature examining BPC-157’s behaviour in tissue remodelling and repair contexts
• Gastrointestinal biology — given its origin in gastric protein, gut-related research has been a consistent area of investigation, including studies on intestinal lining integrity and inflammatory bowel models
• Tendon and ligament research — a significant body of animal model research has examined BPC-157’s behaviour in musculoskeletal tissue contexts
• Inflammatory pathways — research has investigated interactions with nitric oxide signalling and other inflammatory mechanisms
• Neurological research — more recent literature has explored BPC-157 in central and peripheral nervous system contexts, including dopamine and serotonin pathway interactions

The breadth of this research profile is a key reason BPC-157 remains one of the most consistently ordered peptides in the Australian market year after year.

How BPC-157 Is Studied

BPC-157 research has been conducted primarily through in-vitro cell studies and animal models. The compound is typically prepared in sterile solution for research administration, and is available in lyophilised (freeze-dried) powder form for reconstitution prior to use. Australian Peptides supplies BPC-157 in research-appropriate formats with batch documentation available on request.

March 2026: BPC-157 Stock Update

BPC-157 is fully in stock at Australian Peptides as of March 2026. It is one of our most consistently stocked compounds — demand is steady and we maintain reliable domestic inventory to match. Orders are processed and dispatched within 24 hours of placement.

For researchers who have previously sourced BPC-157 from overseas suppliers and dealt with customs delays or cold-chain uncertainty, domestic availability is a straightforward upgrade.

Why Source From Australian Peptides?

• Domestic Australian stock — no international shipping delays or customs risk
• 24-hour dispatch — orders placed today ship tomorrow
• Research-grade quality with batch documentation available on request
• Cold-chain compliant packaging to preserve peptide integrity in transit
• Australian-based support for research sourcing enquiries
• Secure, discreet packaging suitable for laboratory delivery addresses

Frequently Researched Alongside BPC-157

BPC-157 is commonly studied in combination with or alongside other compounds. Researchers investigating BPC-157 frequently also source:

• TB-500 (Thymosin Beta-4) — often studied alongside BPC-157 in tissue repair research contexts
• GHK-Cu — another compound with a long research history across tissue and inflammatory pathways
• AOD-9604 — studied in metabolic and tissue contexts

All of the above are currently in stock at Australian Peptides. Visit the store for the full catalogue and real-time availability.

Buy BPC-157 Now

BPC-157 is in stock and dispatching within 24 hours. Shop now at australianpeptides.com.